Company Overview
Valneva SE operates as a specialty vaccine company dedicated to the development, manufacturing, and commercialization of prophylactic vaccines designed to address infectious diseases with unmet clinical needs. Within the broader healthcare sector, the company specifically functions within the biotechnology industry, focusing on the production of critical immunization solutions. The entity reports a market capitalization of $569.48M and generates annual revenue of $174.66M, though its employee count is not publicly disclosed in the provided data. These financial metrics suggest the company maintains a mid-to-large scale position within its niche, characterized by significant revenue generation relative to its market valuation, indicating a specialized role in the global vaccine supply chain rather than a massive diversified conglomerate. The specific focus on prophylactic vaccines for diseases like Japanese encephalitis, exemplified by its IXIARO product, underscores its commitment to a high-value, targeted market segment where the ability to manufacture and commercialize complex biological products is paramount.
Financial Health
The company reported revenue of $174.66M over the trailing twelve months, yet this top-line figure contrasts sharply with a net income loss of $115,192,000, revealing a cost structure where expenses significantly outweigh gross profits. This substantial gap between revenue and net income is further highlighted by an EBITDA figure of $-64,702,000, indicating that even before interest, taxes, depreciation, and amortization, the core operations are generating negative cash equivalents. Operating metrics show a gross margin of -10.2%, an operating margin of -58.1%, and a profit margin of -66.0%, all of which indicate that the company is currently burning cash on a per-unit basis and has not yet achieved profitability on its sales. The balance sheet shows a cash position of $109.65M against total debt of $207.25M, resulting in a debt-to-equity ratio of 195.21, which signifies a highly leveraged balance sheet where liabilities exceed equity by a wide margin. Despite this leverage, the current ratio stands at 2.38, suggesting that the company maintains adequate short-term liquidity to cover its immediate obligations. Return on equity is reported at -80.2% and return on assets at -11.4%, metrics that reveal management is currently destroying value for shareholders and struggling to generate returns on the capital deployed.
Valuation Assessment
Valuation metrics present a complex picture with a trailing P/E ratio listed as N/A due to the negative earnings, while the forward P/E is 8.09, implying that the market is pricing in a significant turnaround in earnings trajectory over the coming fiscal periods. The price-to-book ratio is 9.25, indicating that the stock trades at a substantial premium relative to its book value, which can be interpreted as the market anticipating future growth or asset appreciation that is not yet reflected on the balance sheet. Alternative valuation measures such as a price-to-sales ratio of 3.26 and an EV/EBITDA of -29.17 further suggest that traditional earnings-based multiples are not applicable, forcing reliance on sales multiples to gauge the company's relative worth. The stock price has fluctuated between a 52-week high of $12.25 and a 52-week low of $5.43, meaning the current price sits in a range that reflects significant volatility and market sentiment shifts during the year. The beta value is 1.27, which indicates that the stock's price volatility is 27% higher than the broader market, exposing investors to elevated risk compared to more stable large-cap equities.
Growth & Income
Revenue growth year-over-year stands at -9.9%, while earnings growth is N/A due to the lack of profitability; consequently, earnings are not growing faster than revenue because both are currently contracting or negative. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders and instead must reinvest all available resources or rely on external capital to fund operations. This lack of dividend income necessitates that investors seek potential capital appreciation solely from share price movements, as the company reinvests earnings—or rather, attempts to cover operational deficits—into growth initiatives. The overall growth and income profile is characterized by negative revenue expansion, negative earnings, and zero dividend distribution, highlighting a company in a developmental or turnaround phase rather than a mature income-generating stage.